BioSpace News Archive

Drug Development

Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01

Spago Nanomedical AB announced that the independent data monitoring committee has recommended a dose escalation in the company’s clinical phase I/IIa study Tumorad-01 with the candidate drug 177Lu-SN201.

January 10, 2024
·
1 min read
Drug Development

STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara

Partners STADA and Alvotech announced that the European Commission issued a marketing authorization for Uzpruvo®, a biosimilar candidate to Stelara®.

January 10, 2024
·
11 min read
New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted orphan drug designation by FDA

The Centre for Chinese Herbal Medicine Drug Development of Hong Kong Baptist University (HKBU) has developed a new drug using effective components of a Chinese herbal medicine, Chaenomelis Fructus, for the treatment of the rare disease, myofibrillar myopathy.

January 10, 2024
·
4 min read
Nanoflex Robotics Receives ISO 13485 CertificationThe innovative medical robotic startup achieved the globally recognized ISO 13485 certification in December 2023

Nanoflex Robotics AG, a remote robotic surgical company based in Switzerland, has received the internationally recognized ISO 13485 certification for its quality management system in designing and manufacturing remote robotic devices for endovascular interventions.

January 10, 2024
·
2 min read
More accurate tumour treatment thanks to superconductive ASG Superconductors technology

ASG Superconductors’ MgB2 superconducting technology is at the heart of the worldwide innovation presented in Dresden in the field of proton therapy and cancer treatment using real-time MRI imaging.

January 10, 2024
·
3 min read
Genetown

Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression

Alkeus Pharmaceuticals, Inc., today announced positive interim data showing gildeuretinol halted Stargardt disease progression for up to six years.

January 10, 2024
·
5 min read
FDA

Providence Medical Technology Announces FDA Clearance of CAVUX® FFS-LX Lumbar Facet Fixation System for 1- and 2-Level Lumbar Spinal Fusion

Providence Medical Technology, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its CAVUX® FFS-LX: Lumbar Facet Fixation System for use in lumbar spinal fusion surgery.

January 10, 2024
·
3 min read
BioMidwest

Zomedica Corp. to Host Conference Call on January 17, 2024, at 4:30 p.m. ET to Provide a Business Update

Zomedica Corp. today announced that it will be hosting a conference call on Wednesday, January 17, 2024 at 4:30 p.m. ET.

January 10, 2024
·
1 min read
Genetown

Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential

Myrobalan Therapeutics today announced completion of a $24 million Series A funding. Funding was led by Co-win Ventures, with participation from new and existing investors including, Guan Zi Equity Investment (Li Shui) Partnership (Limited Partnership), 3E Bioventures Capital, and AB Magnitude Ventures Group.

January 10, 2024
·
5 min read
Drug Development

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Bio-Path Holdings, Inc., today announced completion of the first dose cohort of the dose escalation portion of its Phase 1 clinical trial of BP1002 evaluating the ability of BP1002, a liposomal Bcl-2 nanoparticle antisense, for the treatment of refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia (CLL) patients.

January 10, 2024
·
5 min read